Shanghai Henlius Biotech acquired Greater China rights to two early-stage bifunctional sialidase candidates from Palleon Pharma, a Waltham, MA biopharma, in a deal with $196.5 million in development and sales milestones.

Amid a slow week, Shanghai's HanBio Therapeutics raised $40 million in a Series A financing to advance its innovative biologic products. HanBio is an early R&D company that was incubated by Sunshine Guojian Pharma.

AffaMed acquired greater China rights to an ophthalmic drug from Hanmi Pharma in an $145 million agreement. Sperogenix Therapeutics in-licensed China rights to vamorolone from Santhera in a deal valued at up to $124 million, plus royalties

Broncus Holding, a Hangzhou pulmonary medical device company, completed a $200 million IPO on the Hong Kong exchange that valued the company at nearly $1.3 billion. The IPO was priced at the top end of the range, but Broncus' shares dropped 20%.

Pacific Biosciences, a San Francisco Bay area company offering long-read sequencing platforms, will acquire Omniome for up to $800 million. Zai Lab and Schrödinger formed a collaboration to develop a novel oncology product targeting DNA damage.